Luspatercept to treat anemia after donor stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, single-arm prospective Phase 1/2 study will enroll 46 patients with acute leukemia who have undergone allogeneic hematopoietic stem cell transplantation. All participants will receive subcutaneous luspatercept 1 mg/kg on day +7 (±3 days) and day +28 (±3 days) after transplant. The primary endpoint is the proportion of patients with a hemoglobin increase of ≥1.5 g/dL at 8 weeks post-transplant without transfusion support, with secondary endpoints including time to neutrophil and platelet engraftment and safety outcomes such as adverse events, graft‑versus‑host disease, and infections. Intensive laboratory and clinical follow-up through the first two months will track blood counts, transfusions, engraftment status, T‑cell subsets, and disease assessments including minimal residual disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Clinically diagnosed with acute leukemia.
2. Has undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT).
3. Expected to survive for more than 3 months from the date of signing the informed consent form.
4. Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, and has provided written informed consent.
5. Women of childbearing potential must have a negative serum pregnancy test within prior to enrollment. Female subjects who are surgically sterile or postmenopausal for at least 2 years are considered not of childbearing potential. Male and female subjects of reproductive potential must agree to use effective contraception throughout the study period.
6. Hemoglobin (Hb) level \< 80 g/L.

Exclusion Criteria:

1\. Inadequate organ function, defined as:

1. Creatinine clearance \< 60 mL/min;
2. Left ventricular ejection fraction (LVEF) \< 55%;
3. Oxygen saturation (SpO₂) \< 92% on room air;
4. Total bilirubin \> 2 × the upper limit of normal (ULN);
5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 × ULN. 2. Poorly controlled hypertension, defined as repeated systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg despite adequate antihypertensive therapy, or a history of hypertensive crisis or hypertensive encephalopathy.

3\. History of other malignancies (except for acute leukemia), unless the subject has been disease-free for ≥5 years. However, subjects with the following history/concomitant conditions are eligible:

1. Basal or squamous cell carcinoma of the skin;
2. Carcinoma in situ of the cervix;
3. Carcinoma in situ of the breast;
4. Incidental histological finding of prostate cancer (T1a or T1b as defined by the TNM staging system);
5. Solid tumors considered by the investigator to have no other known active disease.

4\. Major surgery within 8 weeks prior to enrollment. The subject must have fully recovered from any prior surgery.

5\. History of cerebrovascular accident (including ischemic, embolic, and hemorrhagic), transient ischemic attack, deep vein thrombosis (including proximal and distal), pulmonary or arterial embolism, arterial thrombosis, or other venous thrombosis within 6 months prior to enrollment. Note: Prior superficial thrombophlebitis is not an exclusion criterion.

6\. Uncontrolled epilepsy, history of cerebral ischemia/hemorrhage, cerebellar disease, or other active central nervous system disorders.

7\. Cardiac disease within 6 months prior to enrollment, including: myocardial infarction, uncontrolled angina, acute decompensated heart failure, New York Heart Association (NYHA) Class III-IV heart failure, or uncontrolled arrhythmia (as determined by the investigator).

8\. Uncontrolled active systemic fungal, bacterial, or viral infection. 9. Evidence of human immunodeficiency virus (HIV) infection, active hepatitis B, and/or active hepatitis C.

10\. History of pure red cell aplasia (PRCA) and/or anti-erythropoietin antibody.

11\. Any condition or concomitant medication that may interfere with the interpretation of study data.

12\. Known hypersensitivity to luspatercept or any of its excipients.

Where it's running

• Zhujiang Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Zhao Liang, Doctor — Zhujiang Hosptial of Southern Medical University
• Study coordinator: Zhao Liang, Doctor
• Email: 383331047@qq.com
• Phone: 86 13631451531

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Menin inhibitors in pediatric relapsed or refractory acute leukemia

  This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07898436

• Artistic and movement activities to help anxiety in kids with ALL

  Kids aged 8–13 with acute lymphoblastic leukemia test whether a 16-session art and movement program can reduce anxiety compared with standard care.

  Recruiting Phase 3 Children's Cancer Hospital Egypt 57357 · Cairo, Cairo Governorate · NCT07878065

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers

  This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.

  Recruiting Phase 1 Laguna Biotherapeutics, Inc. · Palo Alto, California · NCT07573111

• Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers

  This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07565220

• Menin inhibitor maintenance after allogeneic stem cell transplant

  This project will try menin inhibitor maintenance to see if it helps people with acute leukemia after allogeneic stem cell transplant who have KMT2A or related gene changes.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07559695

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.